{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:17:58Z","timestamp":1777918678017,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Remarkable advancements in the therapeutic armamentarium for medullary thyroid cancer (MTC) have been observed in the last 10 years. The current understanding of driver mutations, such as RET and RAS, has enabled the development of new therapies for advanced and metastatic disease, demonstrating improved efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient Findings:<\/jats:title>\n                    <jats:p>A patient with RET-positive hereditary MTC developed multiple skin cancers (basal cell and squamous cell carcinomas) along with progression of MTC after 12 years of treatment with vandetanib. Once surgery to manage skin cancers has been excluded, the patient received a combination of selpercatinib and cemiplimab, and has been on this treatment at the full dose for 15 months, with ongoing therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>The combination of selpercatinib and cemiplimab was possible, with no new safety signals observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916251378278","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:39:27Z","timestamp":1762756767000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Selpercatinib plus cemiplimab in\n                    <i>RET<\/i>\n                    positive medullary thyroid cancer patient with skin cancers"],"prefix":"10.1177","volume":"111","author":[{"given":"Laura Deborah","family":"Locati","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy"},{"name":"Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Puce","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy"},{"name":"Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Amoroso","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Spedali Civili of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Sottotetti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Spedali Civili of Brescia, Brescia, Italy"},{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"National Cancer Institute. How common is medullary thyroid cancer? https:\/\/www.cancer.gov\/pediatric-adult-rare-tumor\/rare-tumors\/rare-endocrine-tumor\/medullary-thyroid-cancer (2019 accessed 21 April 2025)"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0259"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02426-x"},{"key":"e_1_3_2_7_2","unstructured":"European Medicines Agency. Retsevmo https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/retsevmo (2014 accessed 21 April 2025)"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254"},{"key":"e_1_3_2_10_2","article-title":"Blue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report","volume":"10","author":"Perlmutter JW","year":"2022","unstructured":"Perlmutter JW, Cogan RC, Wiseman MC. Blue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report. SAGE Open Med Case Rep 2022; 10: 2050313X221086316.","journal-title":"SAGE Open Med Case Rep"},{"key":"e_1_3_2_11_2","first-page":"1153","article-title":"Photocarcinogenesis and skin cancer prevention strategies: an update","volume":"38","author":"Martens MC","year":"2018","unstructured":"Martens MC, Seebode C, Lehmann J, et al. Photocarcinogenesis and skin cancer prevention strategies: an update. Anticancer Res 2018; 38: 1153-1158.","journal-title":"Anticancer Res"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02503"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.02.004"},{"key":"e_1_3_2_14_2","article-title":"Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex","volume":"13","author":"Colombo C","year":"2024","unstructured":"Colombo C, Ceruti D, Succi M, et al. Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex. Eur Thyroid J 2024; 13: e230246.","journal-title":"Eur Thyroid J"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090698"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251378278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916251378278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251378278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:43:54Z","timestamp":1777661034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916251378278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/03008916251378278"],"URL":"https:\/\/doi.org\/10.1177\/03008916251378278","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]}}}